RELIEVE-HF is a global, randomized, controlled, double-blinded, 500 patient pivotal study to evaluate the safety and effectiveness of V-Wave’s novel therapy. V-Wave Ltd. announced today that it has enrolled the first patients in its global, 500 patient pivotal study...
$70M Series C financing led by Deerfield Management; V-Wave also announced upcoming launch of the RELIEVE-HF pivotal study. V-Wave Ltd., an Israel-based company that has developed a proprietary, minimally invasive implanted interatrial shunt device for treating...
Recent Comments